Insys Therapeutics (INSY) Reports Q4 Loss of $0.61, Miss on Revenues

March 8, 2018 4:21 PM

Insys Therapeutics (NASDAQ: INSY) reported Q4 EPS of ($0.61), versus ($0.14) reported last year. Revenue for the quarter came in at $31.49 million versus the consensus estimate of $34 million.

Financial & Operating Highlights

For earnings history and earnings-related data on Insys Therapeutics (INSY) click here.

Categories

Earnings Guidance